Aldeyra is a $1.46 high-risk binary biotech: three CRLs impair the base case, but a viable FDA path or AbbVie exercise could support an outsized rerating.
Overview
Aldeyra Therapeutics is a clinical-stage biotechnology company with no commercial product revenue. Its value is concentrated in reproxalap, a first-in-class topical RASP modulator for dry eye disease and allergic conjunctivitis, and ADX-2191, a vitreous-compatible intravitreal methotrexate formulation for PVRL and retinal disease. Reproxalap’s rapid onset and non-steroid mechanism address meaningful limitations of existing therapies, while ADX-2191 could replace inconsistent off-label compounded treatment. **The central problem is regulatory execution: reproxalap has received three CRLs, most recently on March 17, 2026, and commercial consensus revenue for 2026 fell from $68.5 million to under $2.0 million.** Q2 2026 revenue was $0.00 million, net loss narrowed to $5.50 million, and cash was $45.10 million. Debt was eliminated through repayment of the $15.0 million Hercules facility, with runway projected into 2H 2028. At a $1.46 share price, market capitalization is $88.08 million and EV is $42.98 million, although conventional P/E and EV/EBITDA multiples are not meaningful. **Near-term value hinges on the FDA Type A meeting, AbbVie’s option decision, and ADX-2191 SPA execution.**